Avacta is supporting global efforts in combating the COVID-19 pandemic by using its Affimer®  platform to develop diagnostic reagents for COVID-19 ANTIGEN testing.

Avacta has generated a large number of Affimer binders to the SARS-COV-2 virus spike protein including Affimer pairs for sandwich assays and Affimer inhibitors of the spike-ACE2 interaction.

Avacta is working with Cytiva to develop a saliva based point-of-care rapid test intended for screening of large populations to diagnose the COVID-19 coronavirus infection, and has partnered with Adeptrix to develop a high throughput laboratory test for the infection to run on the installed base of mass spectrometers in hospitals and laboratories.

Avacta is actively seeking further partnerships for the Affimer affinity reagents against the SARS-COV-2 spike protein for immunoassay diagnostic development.

Avacta’s COVID-19 programmes are rapidly evolving. Please see the further information below or contact us via the web form.



Videos / media

Get in touch

Contact us using the form below. Alternatively our email address is:

  • This field is for validation purposes and should be left unchanged.